Purple Innovation, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Purple Innovation, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $468.73M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $487.88M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $510.54M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $573.20M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $725.00M | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | $648.47M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | $428.36M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $285.79M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $196.86M | Mar 14, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $188.56M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $181.13M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $171.83M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $208.09M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $293.75M | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | $305.10M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | $188.97M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $112.60M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $85.02M | Mar 14, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($51.41M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($97.90M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($120.76M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($92.47M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $3.11M | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | ($236.87M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | ($22.57M) | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | ($4.32M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($8.82M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($2.33M) | Feb 1, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($43.03M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($92.18M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($113.71M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($42.75M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | ($24.58M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | $71.23M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | $16.21M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | ($16.89M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($8.75M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($2.66M) | Feb 1, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.60M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $12.96M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $11.90M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $8.76M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $6.94M | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | $5.96M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | $3.86M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $2.10M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $1.39M | Mar 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.83M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($17.85M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($54.66M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($28.77M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | ($30.90M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | $81.26M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | $22.88M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | ($21.66M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $5.00M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($811.0K) | Feb 1, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.08M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $7.24M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $14.39M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $35.38M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $53.94M | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | $27.88M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | $10.46M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $11.33M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $7.58M | Mar 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $296.26M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $307.85M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $390.63M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $433.33M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $642.47M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $554.73M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $147.72M | May 10, 2021 |
| FY2019 | Dec 31, 2018 | $71.71M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $37.66M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $155.82M | Feb 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $325.93M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $287.64M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $275.02M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $258.16M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $495.93M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $487.19M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $176.26M | May 10, 2021 |
| FY2019 | Dec 31, 2018 | $73.72M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $51.58M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $6.53M | Feb 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($29.69M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $20.20M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $115.42M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $174.26M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $145.77M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $67.20M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($26.16M) | May 10, 2021 |
| FY2019 | Dec 31, 2018 | ($662.0K) | Mar 9, 2020 |
| FY2017 | Dec 31, 2017 | $5.00M | Feb 1, 2018 |
| FY2017 | Dec 31, 2016 | $5.00M | Feb 1, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.90M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $4.90M | Mar 12, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($625.28M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($573.87M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($475.97M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($355.21M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | ($261.83M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($265.86M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($28.99M) | May 10, 2021 |
| FY2019 | Dec 31, 2018 | ($4.32M) | Mar 9, 2020 |
| FY2017 | Dec 31, 2017 | ($1.83M) | Feb 1, 2018 |
| FY2017 | Dec 31, 2016 | ($2.63M) | Feb 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.35M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $29.01M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $26.86M | Mar 14, 2025 |
| FY2022 | Dec 31, 2022 | $41.75M | Mar 22, 2023 |
| FY2022 | Dec 31, 2021 | $91.62M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $122.96M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $33.48M | May 10, 2021 |
| FY2020 | Dec 31, 2018 | $12.23M | May 10, 2021 |
| FY2019 | Dec 31, 2017 | $3.59M | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | $4.01M | Mar 14, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $126.68M | Mar 31, 2026 |
| FY2024 | Dec 31, 2024 | $70.68M | Mar 14, 2025 |
| FY2023 | Dec 31, 2023 | $30.00M | Mar 12, 2024 |
| FY2022 | Dec 31, 2022 | $24.66M | Mar 22, 2023 |
| FY2021 | Dec 31, 2021 | $94.11M | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | $41.41M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $35.40M | May 10, 2021 |
| FY2018 | Dec 31, 2018 | $26.65M | Mar 14, 2019 |
| FY2018 | Dec 31, 2017 | $8.00M | Mar 14, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | (6) | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | 0 | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | (1) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Feb 1, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | (6) | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | 0 | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | (1) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Feb 1, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | 4.84M | Feb 1, 2018 |
| FY2017 | Dec 31, 2016 | 4.98M | Feb 1, 2018 |
| FY2016 | Dec 31, 2015 | 4.74M | Mar 14, 2017 |